NO2300016T3 - - Google Patents

Info

Publication number
NO2300016T3
NO2300016T3 NO09759335A NO09759335A NO2300016T3 NO 2300016 T3 NO2300016 T3 NO 2300016T3 NO 09759335 A NO09759335 A NO 09759335A NO 09759335 A NO09759335 A NO 09759335A NO 2300016 T3 NO2300016 T3 NO 2300016T3
Authority
NO
Norway
Application number
NO09759335A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2300016T3 publication Critical patent/NO2300016T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/39Steroid hormones
    • C12N2501/392Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO09759335A 2008-06-04 2009-06-03 NO2300016T3 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/132,857 US8168621B2 (en) 2005-09-30 2008-06-04 6-substituted estradiol derivatives and methods of use
PCT/US2009/046120 WO2009149176A1 (en) 2008-06-04 2009-06-03 6-substituted estradiol derivatives and methods of use

Publications (1)

Publication Number Publication Date
NO2300016T3 true NO2300016T3 (enExample) 2018-01-06

Family

ID=41398499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO09759335A NO2300016T3 (enExample) 2008-06-04 2009-06-03

Country Status (13)

Country Link
US (2) US8168621B2 (enExample)
EP (1) EP2300016B1 (enExample)
JP (1) JP5727370B2 (enExample)
KR (1) KR101769152B1 (enExample)
CN (1) CN102076343B (enExample)
AU (1) AU2009256237B2 (enExample)
BR (1) BRPI0913632A2 (enExample)
CA (1) CA2726364C (enExample)
DK (1) DK2300016T3 (enExample)
ES (1) ES2641779T3 (enExample)
MX (1) MX2010013288A (enExample)
NO (1) NO2300016T3 (enExample)
WO (1) WO2009149176A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1392313E (pt) * 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
US20090028895A1 (en) * 2007-07-27 2009-01-29 Smith Walter P Methods and compositions for reducing facial lines and wrinkles
BR112013005843A2 (pt) * 2010-09-14 2019-12-10 Endece Llc derivativos de er-beta 6-substituído por desmetil-estradiol
MX354409B (es) * 2011-03-21 2018-03-05 Endece Llc Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos.
US11624095B2 (en) 2017-09-27 2023-04-11 Case Western Reserve University Method of quantifying HIV reservoirs by induced transcription based sequencing
US20210024568A1 (en) * 2019-07-23 2021-01-28 Endece Llc Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122154C (enExample) 1963-10-18
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8615092D0 (en) * 1986-06-20 1986-07-23 Erba Farmitalia Androst-4-ene-317-diones
GB8801697D0 (en) 1988-01-26 1988-02-24 Erba Farmitalia Improvements in synthesis of 6-methylene derivatives of androsta-1 4-diene-3 17-dione
US4904950A (en) 1988-11-04 1990-02-27 Medical Data Electronics, Inc. Telemetry digital subcarrier demodulator
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
JPH07215992A (ja) 1993-12-07 1995-08-15 Teikoku Hormone Mfg Co Ltd 6−又は7−置換アンドロスタ−1,4−ジエン誘導体
DE19633349A1 (de) 1996-08-19 1998-02-26 Sigma Tau Ind Farmaceuti Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten
EP1124545B1 (en) * 1998-08-11 2004-12-15 EntreMed, Inc. Use of 2-methoxyestradiol as anti-fungal agents
US6784170B2 (en) * 2000-02-11 2004-08-31 Sri International Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
IT1317031B1 (it) 2000-05-17 2003-05-26 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione di (e,z)3-(2-amminoetossimmino)-androstano-6, 17-dione e di suoi analoghi.
WO2002022645A2 (en) 2000-09-14 2002-03-21 Accelerated Pharmaceuticals, Inc. Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity
AU2004275693A1 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
US8088758B2 (en) * 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
WO2005070951A1 (en) 2004-01-16 2005-08-04 Cedarburg Pharmaceuticals, Inc. Exemestane and its intermediates and methods of making the same
US7419972B2 (en) * 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
BRPI0616639A2 (pt) 2005-09-30 2011-06-28 Endece Llc compostos de exemestano de (s)-6-metiloxaalquila e métodos de uso relacionados
US20080119447A1 (en) * 2005-09-30 2008-05-22 James Yarger 6-alkoxyalkyl estradiol derivatives and methods of use
TWI392682B (zh) 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物

Also Published As

Publication number Publication date
AU2009256237A1 (en) 2009-12-10
MX2010013288A (es) 2010-12-21
JP5727370B2 (ja) 2015-06-03
AU2009256237B2 (en) 2015-11-26
BRPI0913632A2 (pt) 2017-01-24
CA2726364C (en) 2016-10-11
WO2009149176A1 (en) 2009-12-10
US8629130B2 (en) 2014-01-14
DK2300016T3 (en) 2017-09-18
JP2011522825A (ja) 2011-08-04
CN102076343B (zh) 2015-04-01
EP2300016A1 (en) 2011-03-30
US20080312202A1 (en) 2008-12-18
US20120270817A1 (en) 2012-10-25
EP2300016B1 (en) 2017-08-09
CA2726364A1 (en) 2009-12-10
EP2300016A4 (en) 2012-01-18
ES2641779T3 (es) 2017-11-13
US8168621B2 (en) 2012-05-01
CN102076343A (zh) 2011-05-25
KR101769152B1 (ko) 2017-08-17
KR20110019767A (ko) 2011-02-28

Similar Documents

Publication Publication Date Title
BRPI0909040A2 (enExample)
BRPI0917573A2 (enExample)
BRPI0908549B8 (enExample)
BRPI0918697A2 (enExample)
BRPI0917525A2 (enExample)
BRPI0920750A2 (enExample)
BRPI0919470A2 (enExample)
BRPI0907698A2 (enExample)
BRPI0923734A2 (enExample)
BRPI0917618A8 (enExample)
BRPI0912727A2 (enExample)
BRPI0908285A2 (enExample)
BRPI0914750A2 (enExample)
BRPI0910485A2 (enExample)
BRPI0919811A2 (enExample)
BRPI0908120A2 (enExample)
BRPI0915616A2 (enExample)
BRPI0904541A8 (enExample)
BRPI0912462A2 (enExample)
BRPI0920914A2 (enExample)
BRPI0916284A2 (enExample)
BRPI0911617A2 (enExample)
BRPI0913605A2 (enExample)
BRPI0914852A2 (enExample)
BRPI0909508A2 (enExample)